Document is current

Article History

Received: 29 May 2024

Accepted: 9 February 2025

First Online: 17 February 2025

Declarations

:

: The study was compliant with the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical guidelines and the International Conference on Harmonization guidelines on Good Clinical Practice. All informed consent forms and protocols were approved by appropriate ethical review boards before initiation of the study. All participants provided written informed consent before any study procedures were performed and before study drug administration.

: Not applicable.

: JDL consulted or served on an advisory board for AbbVie, Amgen, Arena Pharmaceuticals, Bridge Biotherapeutics, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Entasis Therapeutics, Galapagos, Gilead, Janssen Pharmaceuticals, Samsung Bioepis, Merck, Nestle Health Science, UCB, Pfizer, Protagonist Therapeutics, Sanofi, and Scipher Medicine. He has had research funding from Nestle Health Science, Takeda, Janssen Pharmaceuticals, and AbbVie. He has had educational grants from Takeda and Janssen. He has performed legal work on behalf of generic manufacturers of ranitidine and 3 M. He owns stock in Dark Canyon Labs. AV, S Su, and FD are employees and shareholders of Eli Lilly and Company. XZ is an employee of Syneos Health, which received funding from Eli Lilly and Company in connection with this study. AKK, LS, and CC are employees of Evidera, which received funding from Eli Lilly and Company in connection with this study. S Schreiber has been a consultant for AbbVie, Amgen, Arena Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Ferring, Fresenius, Galapagos, Genentech, GSK, Gilead, I-MAB Biopharma, Janssen, Eli Lilly and Company, Merck, Novartis-Sandoz, Pfizer, Protagonist, Takeda, and Theravance.